Human Genome Epidemiology Literature Finder
Records 1 - 10 (of 10 Records) |
Query Trace: Neutropenia and PIK3CA[original query] |
---|
Phase I study of everolimus and mitomycin C for patients with metastatic esophagogastric adenocarcinoma. Cancer medicine 2013 Jun 2 (3): 325-33. Werner Dominique, Atmaca Akin, Pauligk Claudia, Pustowka Anette, Jäger Elke, Al-Batran Salah-Edd |
Multicenter phase II study of second-line cetuximab plus folinic acid/5-fluorouracil/irinotecan (FOLFIRI) in KRAS wild-type metastatic colorectal cancer: the FLIER study. Anticancer research 2014 Apr 34 (4): 1967-73. Iwamoto Shigeyoshi, Hazama Shoichi, Kato Takeshi, Miyake Yasuhiro, Fukunaga Mutsumi, Matsuda Chu, Bando Hiroyuki, Sakamoto Junichi, Oba Koji, Mishima Hideyu |
Phase I/II study of pilaralisib (SAR245408) in combination with trastuzumab or trastuzumab plus paclitaxel in trastuzumab-refractory HER2-positive metastatic breast cancer. Breast cancer research and treatment 2014 12 149 (1): 151-61. Tolaney Sara, Burris Howard, Gartner Elaina, Mayer Ingrid A, Saura Cristina, Maurer Matthew, Ciruelos Eva, Garcia Agustin A, Campana Frank, Wu Bin, Xu Yi, Jiang Jason, Winer Eric, Krop I |
Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. The Lancet. Oncology 2016 Mar . Cristofanilli Massimo, Turner Nicholas C, Bondarenko Igor, Ro Jungsil, Im Seock-Ah, Masuda Norikazu, Colleoni Marco, DeMichele Angela, Loi Sherene, Verma Sunil, Iwata Hiroji, Harbeck Nadia, Zhang Ke, Theall Kathy Puyana, Jiang Yuqiu, Bartlett Cynthia Huang, Koehler Maria, Slamon Denn |
LCCC 1025: a phase II study of everolimus, trastuzumab, and vinorelbine to treat progressive HER2-positive breast cancer brain metastases. Breast cancer research and treatment 2018 Jun . Van Swearingen Amanda E D, Siegel Marni B, Deal Allison M, Sambade Maria J, Hoyle Alan, Hayes D Neil, Jo Heejoon, Little Paul, Dees Elizabeth Claire, Muss Hyman, Jolly Trevor, Zagar Timothy M, Patel Nirali, Miller C Ryan, Parker Joel S, Smith J Keith, Fisher Julie, Shah Nikita, Nabell Lisle, Nanda Rita, Dillon Patrick, Abramson Vandana, Carey Lisa A, Anders Carey |
Phase II trial of biweekly cetuximab and irinotecan as third-line therapy for pretreated KRAS exon 2 wild-type colorectal cancer. Cancer science 2018 Jun . Osumi Hiroki, Shinozaki Eiji, Mashima Tetsuo, Wakatsuki Takeru, Suenaga Mitsukuni, Ichimura Takashi, Ogura Mariko, Ota Yumiko, Nakayama Izuma, Takahari Daisuke, Chin Keisho, Miki Yoshio, Yamaguchi Kens |
Pertuzumab, trastuzumab and eribulin mesylate therapy for previously treated advanced HER2-positive breast cancer: a feasibility study with analysis of biomarkers. Oncotarget 2018 3 9 (19): 14909-14921. Tono Yasutaka, Ishihara Mikiya, Miyahara Yoshihiro, Tamaru Satoshi, Oda Hiroyasu, Yamashita Yoshiki, Tawara Isao, Ikeda Hiroaki, Shiku Hiroshi, Mizuno Toshiro, Katayama Naoyu |
Influence of BRAF and PIK3CA mutations on the efficacy of FOLFIRI plus bevacizumab or cetuximab as first-line therapy in patients with RAS wild-type metastatic colorectal carcinoma and <3 baseline circulating tumour cells: the randomised phase II VISNÚ-2 study. ESMO open 2021 Mar 6 (2): 100062. Sastre J, García-Alfonso P, Viéitez J M, Cano M T, Rivera F, Reina-Zoilo J J, Salud-Salvia A, Quintero G, Robles-Díaz L, Safont M J, La Casta A, Gil S, Polo E, Asensio-Martínez E, García-Paredes B, López R L, Guillot M, Valladares-Ayerbes M, Aranda E, Díaz-Rubio E, |
Neoadjuvant Trastuzumab and Pyrotinib for Locally Advanced HER2-Positive Breast Cancer (NeoATP): Primary Analysis of a Phase II Study. Clinical cancer research : an official journal of the American Association for Cancer Research 2022 6 28 (17): 3677-3685. Yin Wenjin, Wang Yaohui, Wu Ziping, Ye Yumei, Zhou Liheng, Xu Shuguang, Lin Yanping, Du Yueyao, Yan Tingting, Yang Fan, Zhang Jie, Liu Qiang, Lu Jinso |
A Phase I Study of the CDK4/6 Inhibitor, Palbociclib in Combination with Cetuximab and Radiotherapy (IMRT) for Locally Advanced Head and Neck Squamous Cell Carcinoma. Clinical cancer research : an official journal of the American Association for Cancer Research 2023 11 . Nuttapong Ngamphaiboon, Poompis Pattaranutaporn, Somthawin Lukerak, Teerada Siripoon, Artit Jinawath, Lalida Arsa, Prapimporn Ch Shantavasinkul, Naphat Taonam, Narumol Trachu, Natini Jinawath, Arpakorn Kositwattanarerk, Thiparom Sananmuang, Chuleeporn Jiarpinitn |
- Page last reviewed:Feb 1, 2024
- Page last updated:Apr 22, 2024
- Content source: